Application
Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);Application
Figure 1: Western blot analysis using VAV1 mAb against human VAV1 recombinant protein. (Expected MW is 49.3 kDa)Application
Figure 2: Western blot analysis using VAV1 mAb against HEK293 (1) and VAV1 (AA: 121-324)-hIgGFc transfected HEK293 (2) cell lysate.Application
Figure 3: Western blot analysis using VAV1 mouse mAb against Jurkat (1) cell lysate.Application
Figure 4: Flow cytometric analysis of HeLa cells using VAV1 mouse mAb (green) and negative control (red).| Product Name | VAV1 |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | VAV |
| Immunogen | Purified recombinant fragment of human VAV1 (AA: 121-324) expressed in E. Coli. |
| Clonality | Monoclonal |
|---|---|
| Host Species | Unknow |
| Tested Applications | WBFCMICC/IF |
| WB:1:250~1:1000 ICC/IF:1:100~1:200 Notes:Optimal dilutions/concentrations should be determined by the researcher. |
|
| Species Reactivity | Human |
| Alternative Names | VAV |
|---|---|
| Molecular Weight(MW) | 98.3kDa |
| Entrez Gene | 7409 |
|---|
Application
Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);
Application
Figure 1: Western blot analysis using VAV1 mAb against human VAV1 recombinant protein. (Expected MW is 49.3 kDa)
Application
Figure 2: Western blot analysis using VAV1 mAb against HEK293 (1) and VAV1 (AA: 121-324)-hIgGFc transfected HEK293 (2) cell lysate.
Application
Figure 3: Western blot analysis using VAV1 mouse mAb against Jurkat (1) cell lysate.
Application
Figure 4: Flow cytometric analysis of HeLa cells using VAV1 mouse mAb (green) and negative control (red).| Application Notes | WB:1:250~1:1000 ICC/IF:1:100~1:200 Notes:Optimal dilutions/concentrations should be determined by the researcher. |
|---|
| Form | Purified antibody in PBS with 0.05% sodium azide |
|---|---|
| Storage Instructions | 4℃; -20℃ for long term storage |
